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Abstract
Tumour-infiltrating immune cells have been widely implicated to play a significant role in carcinogenesis, through both pro- or 
anti-tumour effects. The multi-faceted effects of lung cancer associated T lymphocytes have been extensively studied, and yet, 
the role of B lymphocytes remains an area less studied. In this review, we will describe the current understanding of the role 
of tumour-infiltrating B lymphocytes in NSCLC, discuss their prognostic significance, their functionality within the tumour 
microenvironment and ultimately how we might harness B-cell biology to develop B-cell therapeutic strategies in cancer.
Keywords B lymphocyte · Non-small-cell lung cancer (NSCLC) · Humoral Immunity · Immunoglobulin · Tumour 
-infiltrating B lymphocyte (TIL-B)
Introduction
Immune responses within the tumour microenvironment 
(TME) are important determinants of tumour behaviour, pro-
gression, and aggressiveness [1]. The role of T-cell-mediated 
immune responses in solid tumours is well established and 
has become the driving force for major therapeutic advances, 
specifically with the advent of immune checkpoint inhibitors 
[2]. The success of single agent and combination checkpoint 
blockade, which enables antigen-experienced microenviron-
mental T cells, has transformed the treatment paradigm of 
advanced NSCLC both as a front-line option and in the plati-
num-refractory setting. As a consequence, our understanding 
of the biology of these T cells has expanded exponentially. 
In contrast, our knowledge of B-cell biology in cancer is 
less well developed. Tumour-infiltrating B cells have been 
observed in all stages of lung cancer development, with 
their presence differing according to stage and histological 
subtype. Given that they play a role in both humoral and 
cellular immunity B-cell parameters may be important in 
determining both responsiveness to and toxicity of check-
point blockade. Manipulation of B-cell biology might offer 
significant immune-therapeutic opportunities [3]. Thus, 
understanding B-cell biology in NSCLC is of fundamen-
tal importance in informing potential novel multi-faceted 
approaches to favourably reset the immune contexture of the 
cancer microenvironment.
B‑cell ontogeny
In the bone marrow, haematopoietic stem cells serve as the 
common lymphoid progenitor and continually give rise to B 
cells throughout life [4]. B-cell development and differentia-
tion are subsequently regulated through the B-cell receptor 
(BCR). On leaving the bone marrow, B-cell development 
takes place in B-cell follicles within secondary lymphoid 
organs (SLOS), where germinal centres (GC) develop in 
response to antigen encounter. Mature B cells undergo a 
process known as somatic hypermutation (SHM), where 
enzyme induced mutations are introduced in the heavy and 
light chain variable regions to further diversify the immuno-
logical repertoire. The same enzyme mediates immunologi-
cal class switch recombination (CSR), replacing the μ con-
stant region for another heavy chain region to generate IgA, 
IgE or IgG. The cells with the highest affinity B-cell recep-
tors (BCR) are positively selected (this requires signalling 
through the BCR for the cell to survive, negative selection 
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occurs when the B-cell antigen receptor binds self-antigen 
and, therefore, undergoes cell death) and undergo clonal 
expansion in the germinal centre. These class-switched B 
cells can then give rise to long-lived plasma cells or memory 
B cells [5]. Germinal centres, which are normally found in 
SLOS such as the spleen and lymph nodes, can also occur as 
tertiary lymphoid structures (TLS) in tumours; this has been 
reported in colon, breast and NSCLC [6–8]. The de novo 
formation of ectopic lymphoid tissue can occur at the site of 
inflammation in potentially any organ system [9]. There is 
evidence that the adaptive immune system can be initiated 
independent of SLOS in these TLS in NSCLC [7].
B‑cell function
Antigen presentation
T cell immune responses can be activated by B cells. Anti-
gen-specific interactions require antigen internalisation via 
the BCR with subsequent presentation to T cells in an MHC-
restricted manner [10]. Depleting host B cells from normal 
adult mice results in sub-optimal CD4 + T cell activation 
during immune responses to low-dose foreign antigen [11]. 
Activated B cells derived from peripheral donor blood from 
healthy controls present antigens to CD4 + and CD8 + T 
cells [12]. B cells and dendritic cells further provide a co-
stimulatory signal which is critical to the expansion of an 
effector T cell population, namely the cross-linking of CD40 
with CD154 (CD40 Ligand) on CD4 + T cells [10] which in 
turn induces the expression and thence stabilisation of CD86 
(B7.2) and CD80 (B7.1) on the B-cell surface (second co-
stimulatory signal).
Antibody production
B cells exist as long-lived plasma cells to produce antigen-
specific antibody. The functional BCR can recognise an 
array of foreign antigens in the circulation and lymphoid 
organs, which then triggers antigen-specific antibody 
responses. Following antigen binding, BCR stimulation 
results in a signalling cascade mediated by membrane 
bound protein tyrosine kinases, Spleen Tyrosine Kinase 
(SYK), Bruton Tyrosine Kinase (BTK) and PI3K, in par-
ticular PI3Kδ which is a p110 isoform with high lymphocyte 
specificity [4]. This in turn results in B-cell differentiation 
into plasma and memory cells. The plasma cells will traf-
fic to the bone marrow or reside in SLOS, where they will 
continue to secrete antibody. BCR signalling controls this 
process from early B-cell precursor development to terminal 
plasma cell differentiation, long-lived IgG plasma cells are 
devoid of the BCR [5].
Immunosuppression
B cells play a vital role in the development of the immune 
system but are also responsible for immune homeostasis. 
Their immunosuppressive role has been illustrated by their 
ability to function as regulatory cells or Bregs, whereby they 
influence T cell differentiation and thus T-cell-mediated 
inflammatory responses through IL-10 production [13]. 
B regulatory cells are associated with limiting excessive 
inflammation [14] and mice lacking IL-10 producing Bregs 
develop chronic inflammation [15]. IL-10 producing Bregs 
induce the Treg phenotype by skewing T cell differentiation 
in mice [16] and humans [17]. Other cytokines that have 
been implicated in B-cell specific immunosuppression are 
TGF-beta and IL-35. TGF-beta when produced by B cells 
can induce CD4 + T cell apoptosis [18] and CD8 + T cell 
anergy [19]. Chimaeric mice lacking either p35 or EBi3 
(IL-35 subunits) in B cells develop accentuated autoimmune 
responses and have greater protection against Salmonella 
induced sepsis [20].
IL-10 has been useful for Breg characterisation in both 
mice and humans; however, this can be up or down-regulated 
during immune activation and is not a stable inducible trait 
[14, 21]. A lineage-specific marker for Bregs equivalent to 
Foxp3 has not been identified. B cells are polarised to Bregs 
in response to microenvironmental cues: Bregs have been 
derived by treating human derived peripheral B cells with 
tumour-conditioned media; these Bregs were able to sup-
press the activity of human T cells in vitro and they exhib-
ited low surface expression of CD20 unlike healthy control 
human B cells [22, 23]. These tumours evoked Bregs did not 
utilise IL-10 dependent suppression but instead primarily 
functioned to promote the differentiation of Tregs (CD25+) 
via the TGFβ signalling axis [22].
Pre‑clinical studies of the role of B cells 
in cancer
There appears to be a significant difference in the role of B 
cells in animal models which represent different stages in the 
development of cancer. In murine models of pre-malignancy, 
B cells appear to drive inflammation which in turn induces 
pre-malignancy.
Pre‑malignancy models
Early evidence from the K14-HPV16 model (these RAG-1 
knockout (KO) mice in which carcinogenesis is initiated 
by HPV lack T and B cells) has shown that the lack of 
an adaptive immune response results in failure to initiate 
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leucocyte infiltration during pre-malignancy [24] and this 
halts progression towards carcinogenesis. Adoptive trans-
fer of B lymphocytes or serum from HPV16 mice into 
HPV16/RAG1−/− mice resulted in significant infiltration 
of CD45 + leucocytes, macrophages and granulocytes in the 
dermal stroma as well as detectably higher levels of serum Ig 
which then enhanced malignant progression. In this model of 
squamous carcinogenesis, B cells were shown to play a role 
in activating Fcγ receptors (FcγRs) on resident and recruited 
myeloid cells likely via circulating immune complexes (CIC) 
detected in the serum of HPV16 mice and formed from 
IgG bound to cognate HPV16 antigens. These CICs were 
localised to both the epidermal and dermal components of 
neoplastic skin. The recruitment of these chronically acti-
vated leucocytes was dependent on FcγR expression [25], as 
shown by the reduced level of inflammatory cell infiltration 
in neoplastic skin in FcγR−/− KO mice. Subsequently it 
was shown in K14-HPV16 mice that premalignant dysplasia 
could be prevented through B-cell depletion [26]. Admin-
istration of anti-CD20 monoclonal antibodies depleted B 
cells in peripheral blood and SLOS with resultant reduced 
levels of circulating IgG, immune complex deposition and 
trafficking of myeloid cells (CD11 +), CD45 + leucocytes, 
mast cells and GR1 + cells to neoplastic skin [26].
In a DMBA/TPA murine model of skin carcinogen-
esis adoptive transfer of B cells from DMBA/TPA wild 
type (WT) mice into TNF-α knockout mice significantly 
increased papilloma development (p < 0.05), an effect not 
seen when B cells from the TNF-α knockout mice were 
transferred to RAG2−/− mice [27]. TNF-α is a potent 
inflammatory cytokine and tumour promotor, Bregs are 
known producers of TNF-α. Selective TNF-α deletion in 
CD19 + -Cre B cells significantly reduced papilloma devel-
opment compared to B cells from WT mice (p < 0.002). 
TNF-α knockout mice showed increased levels of IFN-γ and 
CD8 + T cell skin infiltration, but also a significant reduction 
in the number of splenic CD19 + CD21hi, IL-10 producing 
Bregs compared with WT mice (p < 0.01). Further experi-
mental data showed that TNF-α blockade of LPS-induced 
B-cell activation significantly reduced IL-10 production with 
no difference in IL-2, -4, -5, -12 or IFN-γ. The results of this 
study identify Bregs as contributory to squamous carcino-
genesis, with their activity likely regulated by TNF-alpha 
with Bregs themselves acting as a cellular source of TNF-α.
The impact of B cells in established cancer appears to be 
very different to their role in pre-malignant disease.
Established cancer models
B-cell depletion using anti-CD20 in a B16 melanoma 
murine model resulted in increased tumour burden and the 
development of pulmonary metastasis [28]. CpG (TLR 9 
ligand) primed B cells caused tumour regressions in a B-cell 
deficient melanoma model [29]. CpG treatment of B cells 
induced higher expression of MHC class I and II as well 
as CD20. It was also noted that in the mice that underwent 
adoptive B-cell transfer, the lung tumours expressed signifi-
cantly lower levels of BCL-2 (an anti-apoptotic protein) and 
increased levels of TRAIL (TNF-related-apoptosis-induc-
ing-ligand, a pro-apoptotic protein), TRAIL expression is 
highest in germinal centre B cells and thus the upregulation 
in these murine lung tumours is likely B-cell driven [29].
In a 4T1 breast cancer model treatment with an anti-CD20 
antibody resulted in massive cancer growth and metastasis. 
Eradication of  CD20hiB cells, enriched for a select popula-
tion of  CD20LO Bregs which escaped CD20-directed deple-
tion and thus significantly suppressed CD4 + and CD8 + T 
cell activity thus abrogating anti-tumour responses [23]. Tar-
geted delivery of CpG-ODN to CXCR5 expressing cells, 
reversed the phenotype of these tumour evoked Bregs (which 
upregulated CD20) and restored effector B-cell responses. 
This was demonstrated by a complete abrogation of tumour 
metastasis in anti-CD20 treated 4T1.2 cancer bearing mice 
after adoptive transfer of CpG treated B cells [30]. Using 
the same murine model, Tao et al. demonstrated that IL-10 
inhibition significantly augmented the therapeutic efficacy 
of adoptive B-cell transfer, as demonstrated by increased 
trafficking of CD8 + T cells into the tumour microenviron-
ment as well as in vitro antigen-specific B-cell dependent, 
FasL-mediated tumour cell killing [31]. Activated B cells 
from this model produce IgG and mediate complement-
dependent tumour cell lysis in vitro [32]. Finally, the use of 
intra-tumoural TLR9 immune stimulation in combination 
with PD-1 blockade has demonstrated clinical efficacy in 
advanced melanoma, with increased B-cell infiltration noted 
on post-treatment tumour biopsies [33]. Phase I clinical trial 
data from patients with metastatic solid tumours showed a 
non-significant increase in TLR9-expressing naïve B cells 
during therapy [34].
Tumour infiltrating B lymphocytes in human 
lung cancer
Table 1 summarises studies that have identified TIL-Bs 
in tissue and examined their associated prognostic sig-
nificance. These studies largely focus on NSCLC which is 
where the correlation between TIL-Bs and disease-specific 
outcome has been shown to be strongest by comparison 
with other forms of Lung cancer. However, groups have 
investigated the immune milieu in large cell carcinoma and 
Small Cell Lung Carcinoma (SCLC). In the former, Eerola 
et al. have demonstrated that TIL-Bs do correlate with bet-
ter overall survival [35], whereas in SCLC, B-cell infiltra-
tion is significantly reduced compared with CD8 + T cell 
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and Macrophage infiltration and TIL-B number has not 
been shown to associate with survival (p = 0.634 by log 
rank) [36].
In Table 1, the majority of studies have used a combina-
tion of immunofluorescence or immunohistochemistry to 
identify these cells in tissue. Of the 28 studies identified, 
18 have used IHC as a primary method, mRNA sequencing 
has been employed in 4 studies and 2 have employed qt-
PCR [37–41]. An anti-BCL-6 antibody and an anti-CD21 
antibody were utilised to identify Germinal Centre B cells 
and mature B cells, respectively. Immunohistochemistry was 
used to determine B-cell density, location and phenotype 
within NSCLC tissue [8]. Studies have utilised PCR micro-
array and Mrna-sequencing techniques to identify primarily 
humoral immunity related gene signatures in NSCLC speci-
mens [42, 43]. CD20 + B-cell infiltration has been shown to 
be positively prognostic in NSCLC by a number of different 
groups [38–43]. Disease-free and overall survival was signif-
icantly higher in non-smokers with non-squamous NSCLC 
[45]. Significantly improved survival has also been shown in 
large cell carcinomas with higher degrees of CD20 + B-cell 
infiltration [35]. Associations have been made between TLS 
(GCs forming as ectopic foci of follicular B cells and clus-
ters of mature DC-Lamp+ve Dendritic cells and T cells in 
cancer tissue, in response to antigen stimulation) in NSCLC 
and improved long-term survival. The presence of both 
types of antigen-presenting cells and mature dendritic cells 
in these TLS strongly predicts the outcome of patients [7, 
44]. A low density of both follicular B cells and mature 
dendritic cells allows the identification of patients at high 
risk of poor survival. A higher prevalence of intra-tumoural 
GC formation was found in NSCLC stage I tumours com-
pared with higher stage (II–IV) tumours (p < 0.02) [8]. In 
a recent study [49] the expression of a tumour-induced 
plasmablast-like B-cell signature (TIPB) was significantly 
correlated with the expression of CD8a signatures and the 
density of CD8 + cells. High expression of the TIPB signa-
ture was correlated with overall survival in the melanoma 
TCGA data set. Importantly, a cohort of melanoma patients 
treated with anti-CD20 antibodies, showed significant on-
treatment down-regulation of the TIPB signature: the signa-
ture was highly correlated with tumour inflammatory score, 
interferon gamma and T cell effector signatures all of which 
significantly decreased on anti-CD20 therapy. There was a 
marked depletion in both CD4 + and CD8 + cell density at 
the invasive tumour-stroma margin and a reduction in the 
TLS area, an effect which was prolonged. In support of this 
data suggesting the importance of B cells in a successful 
anti-cancer immune response, long-term follow-up of CD20 
depletion with Rituximab in patients with lymphoma, it was 
shown that CD20 depletion was an independent risk factor 
for the development of secondary solid tumour malignancy 
in both univariate and multivariate analyses [50].
Finally, the prognostic impact of follicular B cells was 
evaluated in two patient cohorts; early stage untreated 
NSCLC and advanced stage NSCLC treated with neoad-
juvant chemotherapy. “Foll-B-Hi” patients had signifi-
cantly prolonged survival in early stage disease, (97% DFS 
at 4 years compared with 62% in the “Foll-B-Lo” group), 
and in advanced stage disease, a benefit was demonstrated 
albeit not significant (56 month median DFS compared with 
23 months in the “Foll-B-Lo” group). The global increase 
in follicular B-cell density was associated with an overall 
increase in mature DC density. When the combined immune 
populations were taken into account and correlated with 
survival, “Foll-B-Hi/mDC-LampHI” patients had the high-
est median survival, 100% of early stage patients (p < 0.04) 
and 55% of advanced disease patients (p = 0.007) were alive 
after a follow-up of 50 and 60 months, respectively [44]. 
“Foll-B-Lo/mDC-LampLO” patients had the worst prognosis.
Some studies have not demonstrated a prognostic impact 
of B-cell density on NSCLC outcomes [48, 51–54]. How-
ever, it may be that the lack of prognostic impact may relate 
to the high density of Bregs in such studies and it would 
appear to be essential that Breg density be considered sepa-
rately [48, 51, 52]. An explicit analysis of whether Breg 
density is negatively prognostic for outcome, however, has 
not been performed. Finally, the prognostic impact may 
be dependant not only on enumeration of the appropriate 
B-cell subsets (TIMPs, follicular) but also by enumeration of 
tumour-associated B cells in the appropriate compartment, 
as opposed to analysis of un-segmented tumoural B-cell den-
sity. Most B cells are found at the invasive tumour-stroma 
margin, and it is here that the cancer cells are likely to polar-
ise B cells to the immune-stimulatory TIPB phenotype.
B‑cell functionality: human NSCLC
Antibody specificity and antigen presentation
Tumour antigen-specific B-cell responses are evidenced by 
the production of tumour-specific antibody and the oligo-
clonality of TIL-Bs in the TLS [55]. B cells cultured from 
TLS’ have been shown to produce tumour-specific IgG and 
IgA antibodies [44]. LAGE-1 was identified as the most 
immunogenic tumour antigen in NSCLC, followed by 
MAGE family antigens, p53 and NY-ESO-1 [44]. Plasma 
cell and Ig expression associates favourably with outcome 
in NSCLC [43, 56, 57]. IgG4 + plasma cell infiltration cor-
relates favourably with prognosis [57].
In NSCLC tissue TIL-Bs present antigen to CD4 + TILs 
with resultant effector responses [55]. CD4 + T cells, B 
cells and DCs were co-cultured together with protein ± co-
stimulation with an anti-CD40/anti-CD28 antibody. Anti-
HLA-DR, -DP and –DQ was used to block MHC class II 
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antigen presentation. T cell responses were stratified accord-
ing to “activated” (spontaneous presentation of antigen to 
CD4 + T cells), “antigen-associated” (presentation of anti-
gen following re-stimulation by the antigen itself) and “non-
responsive”. Activated TIL-Bs (CD19 + CD20 + CD69 + C
D27 + CD21 +) and antigen-associated B cells mediated an 
effector T-cell response (IFN-γ producing CD4 + T cells). 
Conversely, exhausted phenotype TIL-Bs (CD19 + CD20 + 
CD69 + CD27T − CD21−) were associated with a regula-
tory T-cell phenotype (Foxp3 + CD4 + TILs) [55]. Exhausted 
TIL-Bs were still able to antigen present but controlled host 
damage from chronic antigen exposure by inducing a Treg 
phenotype and ultimately dampening anti-tumour immunity 
[55].
Immunosuppression
In NSCLC, significantly higher frequencies of peripheral 
Bregs (CD19 + CD24hi CD27 +) and CD19 + IL-10 + B 
cells were detected compared with healthy controls [58]. 
IL-10 + B-cell infiltration has positively correlated with 
CD25 + Treg expression and advanced clinical stage [59]. 
Multiple subsets exist with similarities in effector func-
tion and phenotype; in humans Br1 cells (CD19 + CD25hi 
 CD71hi) are strongly IL-10 positive. The differentiation 
of activated B cells into plasma cells is controlled by the 
expression of transcription factors, IRF4 and BLIMP-1 
which are also critical for B-cell suppressive functions and 
some T cell suppressive functions (IRF4 expression in Tregs 
is dependent on Foxp3) [92]. B cells that co-express IRF4 
and BLIMP-1 are the main source of B-cell derived IL-10 
in vivo, and plasma cells are, therefore, a significant con-
tributor, however, not all plasma cells produce IL-10 [60]. 
Currently, the signals that are required for differentiation 
into these regulatory B cells are not known.
Numerous studies have phenotypically characterised vari-
ous Breg subsets in health and disease, this is displayed in 
Table 2 [58, 59, 61–80]. The findings from these studies of 
human Bregs in cancer underscores the ability of different 
Breg subsets to mediate immunosuppression in support of 
Table 2  Human breg phenotypes in cancer and disease
MEDLINE Search 2000–2019 retrieved the papers populating Table 2
Phenotype Mechanism of suppression Disease process Author
CD19 + CD24hi CD38hi (Immature 
subtype)
IL-10, PD-L1 SLE Blair et al. [61]
CD1d SLE Bosma et al. [62]
IL-10, TGF-P, CD40/CD40L Hepatocellular carcinoma Shao et al. [63]
TGF-P Breast cancer, Gastric cancer Olkhanud et al. [64], Wang et al. [65]
IL-10 Non-small cell lung cancer, 
Oesophageal cancer, Ovarian 
cancer
Liu et al. [59], Qian et al. [66], Zhou 
et al. [58], Wei et al. [67]
CD19 + CD5+ IL-10, STAT3 Lung, Prostate cancer Zhang et al. [68]
IL-10, TGF-P Breast cancer Lee-Chang et al. [69]
CD19 + CD5 + CD1dhi IL-10 Chronic inflammation within gut-
associated lymphoid tissue
Yanaba et al. [70], Mizoguchi et al. 
[71]
CD19 + CD35+ IL-35 Pancreatic Cancer Wang et al. [72], Pylayeva-Gupta 
et al. [73]
CD19 + CD24hi CD27 + (B10 cells) IL-10 SLE, Rheumatoid arthritis, primary 
Sjogren’s Syndrome, Multiple 
sclerosis, Autoimmune vesiculob-
ullous skin disease
Iwata et al. [74]
CD19 + CD38 + CD1d + IgM + CD1
47 + (GrB + B cells)
IL-10, GranzymeB Breast, Ovarian, Cervical, Colorec-
tal, Prostatic carcinomas
Lindner et al. [75]
CD19 + CD25hi CD71hi CD73lo 
(Br1 subtype)
IL-10, IgG4 Human model of allergic inflam-
mation in response to bee venom 
antigen
van de Veen et al. [76]
CD19 + CD24hi CD27int CD38hi 
(Plasmablast subtype)
IL-10 Healthy human donor peripheral 
blood
Matsumoto et al. [77]
CD39 + CD73+ Adenosine Healthy human donor peripheral 
blood
Saze et al. [78]
(iBreg subtype) TGF-P, IDO Healthy human donor peripheral 
blood
Nouel et al. [80]
CD19 + TIM-1+ IL-10 HIV-1 Infection Liu et al. [79]
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tumour growth through a variety of mechanisms; suppres-
sive cytokine production (IL-10, TGF-β, IL-35), suppression 
of T cells and NK cells and the expansion of suppressive 
Tregs and myeloid-derived suppressor cells [30], expression 
of inhibitory ligands such as PD-L1 to dampen anti-tumour 
immunity [81] and STAT3 mediated promotion of angio-
genesis and Treg augmentation [22, 68, 82]. It is unclear 
whether Bregs enhance tumour progression directly or if an 
increase in the Breg population is merely reflective of the 
immune response being mounted against the tumour [83].
B‑cell milieu in NSCLC
B cells can exist in a continuum of naïve cells to terminally 
differentiated plasma cells within the TME and more specifi-
cally within the TLS [44]. Determining the ratio between 
these so-called “anti-tumour” TLS derived TIL-Bs and the 
“pro-tumour”, inhibitory Bregs is important to understand 
the biology and long-term outcome from this disease. This 
balance is likely influenced by the microenvironmental cues 
which play a role in determining B-cell polarity. CXCL13 
and Lymphotoxin have been identified as two factors critical 
to the formation and development of lymphoid follicles in 
the gut [84], and in lung cancer, B cells produce CXCL13 
and Lymphotoxin via TLR4 signalling which acts as a posi-
tive feedback loop to support the formation and high density 
of TLS [85, 86]. CXCR5 expressing B cells stimulated by 
CXC13 coupled CpG-ODN can trigger the cytolytic effect 
of CD8 + T cells leading to the abrogation of metastasis in 
4T1.2 tumour-bearing mice [23]. Resveratrol, Lipoxin, Glu-
cosides of Paeony have also inhibited Bregs through STAT3 
and/or ERK inactivation leading to a reduction in IL-10 and 
TGF-β levels thus exerting an anti-tumour effect [87]. B-cell 
homeostasis and thus polarity will largely be determined 
by the degree of inflammation within the tumour, factors 
such as tissue hypoxia, intra-tumoural vascularity, cytokine 
milieu and cellular infiltration are all factors which are likely 
to exert control over the pro versus anti-tumour B-cell bal-
ance but as yet there is little evidence describing the Breg/B 
effector ratio in tumour biology, and this is likely due to the 
transient inducible nature of Bregs.
The interplay of B cells and checkpoint 
blockade
Immune checkpoint blockade antibodies have improved 
cancer therapy by overcoming the inhibition of T cell 
effector functions, yet a significant proportion of patients 
still do not respond to such therapies. In the first study to 
investigate whether B-cell density impacts outcome with 
checkpoint blockade, B-cell content was determined in 
34 melanoma patients undergoing PD-1 blockade mono-
therapy and evaluated for response [88]. Dichotomising 
the patients at the median of CD20 positive cells in at 
least one histospot there was no difference in response or 
survival between those with high and low B-cell density. 
The comments made earlier about enumeration of spe-
cific B-cell populations in specific microenvironmental 
segments made earlier also apply here. B-cell depletion 
in the MC38 (colon carcinoma) and YUMMER1.7 (mela-
noma) models did not impact the efficacy of anti-PD-1 
treatment. Anti-PD-1 outcomes were similar in muMT 
mice (mice lacking B cells) and WT mice bearing MC38 
tumours [88]. Larger data sets in other cancers need to 
be interrogated to fully understand whether there is any 
impact of specific intra-tumoural B-cell populations on 
the outcome of checkpoint blockade. This is particularly 
the case given earlier data showing that clinical benefit 
with ipilimumab was greater in melanoma patients with 
sero-positivity against NY-ESO [89]: as mentioned above, 
the CTags appear to be potent immunogens stimulating 
antibody responses. Furthermore, gene-expression profil-
ing in urothelial carcinoma and melanoma patients under-
going both anti-PD-1/PD-L1 and anti-CTLA4 therapy 
identified a memory B-cell (MBL) signature which was 
significantly and reproducibly elevated in patients showing 
clinical benefit [90]. It significantly outperformed other 
immune cell signatures and remained significantly asso-
ciated with outcome when including tumour mutational 
burden, copy number aberration burden and checkpoint 
expression. Samples enriched for an innate PD-1 resist-
ance scores had significantly lower levels of MBL scores. 
The MBL score positively correlated with BCR heavy 
chain expression and the expression of T cell activation 
genes, MHC class II and genes responsible for B-cell pro-
liferation and activation within the TME. Finally, high 
expression of the TIPB signature was associated with 
improved survival in melanoma patients treated with anti-
PD-1, and plasmablast-like and naïve B-cell frequencies 
were significantly higher in patients responding to immune 
checkpoint blockade [49]. The use of anti-PD-1 treatment 
in murine models has shown to increase total IgG and 
OVA-specific IgG production in OVA-immunised mice 
[91]. The enhanced humoural response in these mice is 
thought to be mediated by CD4 + ICOS + T cells which are 
presumably of the T follicular helper (Tfh) phenotype that 
go on to augment terminal B-cell differentiation in the ger-
minal centre [91]. PD-1/PD-L1 interactions between Tfh 
and Bregs control this axis [92, 93] and by blocking this 
checkpoint, Tfh cells are released from Breg-induced sup-
pression. This demonstrates the importance of heterogene-
ity of the B-cell repertoire and how checkpoint blockade 
can impact downstream immune responses by targeting 
select populations. Importantly, none of the above studies 
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have examined B-cell density as predictive of response to 
checkpoint blockade in NSCLC or to combination chemo/
immunotherapy which has become a 1st line standard of 
care in this disease.
Given that PD-1 is expressed on B cells and can limit 
B-cell responsiveness [94, 95], and furthermore, the cer-
tain autoimmune conditions are mediated via auto-antibody 
formation, the association of B-cell sub-populations with 
checkpoint blockade toxicity has become a focus of inves-
tigation. Das et al. demonstrated in melanoma patients, a 
detectable decline in circulating B-cell numbers together 
with an increase in  CD21LO B cells and plasmablasts after 
the first cycle of combination checkpoint blockade therapy 
[96]. These treatment induced changes in B-cell numbers 
preceded and correlated with both the frequency and tim-
ing of immune related adverse events (irAE). Early B-cell 
changes correlated with a higher rate of grade 3 or higher 
irAEs 6 months after starting treatment. Contrastingly, 
several groups have shown through case report series’ that 
B-cell depletion therapy using Rituximab successfully 
treated B-cell-mediated irAEs in NSCLC [97, 98], SCLC 
[99], Melanoma [100] and Urothelial Carinoma [101]. This 
recapitulates the idea of B-cell enumeration and selective 
targeting of certain microenvironmental B-cell popula-
tions. Bregs which by nature are immunosuppressive and 
dampen down inflammation would limit anti-tumour activity 
in response to PD-1 blockade but effector B-cell popula-
tions with robust humoural responses and T cell activation 
mechanisms are driving autoimmunity and irAE in response 
to PD-1 blockade. These intriguing analyses need to be vali-
dated, extended and applied to other cancers amenable to 
checkpoint blockade and the mechanisms underlying these 
observations identified.
Conclusions
Studies in mouse models of pre-malignancy suggest that 
B-cell-mediated inflammation may be important in promot-
ing the progression to invasive malignancy. Given the huge 
promise of reversing the pre-malignant phenotype to reduce 
the cancer burden, there is an urgent need to understand the 
role of B cells in human metaplasia, dysplasia and in situ 
cancer and how they mediate progression through these 
stages to decide whether B-cell-directed strategies may be 
of value in reducing the progression of pre-malignancy.
Studies examining B cells with a regulatory phenotype 
(Bregs) consistently suggest that Breg infiltration may 
enhance tumour progression. The factors that induce Bregs 
in human malignancy need to be defined. Specifically 
are there particular microbes, TLR ligands or cancer cell 
produced cytokines in the TME that polarise B cells to a 
Breg phenotype [14, 102]. Currently used B-cell depleting 
antibodies cannot distinguish between effector and regu-
latory B-cell subsets; therefore, meticulous phenotypic 
characterisation and study of this subset in the TME [14, 
102] is required to identify Breg specific targets that can 
be exploited to selectively deplete Breg populations but 
more fundamentally to fully understand the role of Bregs in 
human cancer. There are some current potential anti-Breg 
strategies. In vivo murine studies have displayed selective 
Breg depletion using LXA4 without affecting conventional 
B-cell proliferation, differentiation and germinal centre 
formation thus promoting anti-tumour responses [87]. An 
alternate to Breg depletion would be repolarisation of this 
subpopulation into B effector cells, as has been shown with 
TLR9 ligands in vitro [22, 23]. Adoptive transfer of CpG-
pulsed B cells with effector phenotypes into patients with 
established cancer could be employed to shift the balance 
in favour of an anti-tumour B-cell response within the TME.
More work is needed to understand the anti-tumour 
impact of antibodies against tumour associate antigens, 
particularly CTags which appear to be strong immuno-
gens, and to identify new humoural immunity targets. 
The disappointing results of the MAGRIT trial vaccinat-
ing NSCLC patients in the adjuvant setting [103] should 
not be taken as suggesting that harnessing the anti-tumour 
antibody response should be deprioritised: mono-epitopic 
vaccination as cancer therapy has a long history of fail-
ure. Multi-valent vaccines, preferably against personalised 
B-cell antigens, are one option. Building on the model of 
the chimaeric antigen receptor T cells (CART), highly spe-
cific B-cell receptors to critical tumour antigens could be 
cloned into autologous B cells and transferred into patients 
with resultant high specificity and high affinity anti-tumour 
Ig production. Alternatively, antibodies could be produced 
ex vivo and adoptively transferred. Given the role of B-cell 
PD-1 expression in mediating B-cell hypo-responsiveness, 
the role of PD-1 blockade in augmenting these strategies 
should be explored, as a research priority. Understanding 
B-cell biology will help to refine the understanding behind 
the effects of checkpoint blockade on the immune milieu. 
Toxicity from these therapies is the Achilles heel of this 
treatment strategy. As was alluded to earlier, work in mice 
and humans has demonstrated that PD-L1hi Bregs play a role 
in the suppression of humoral immunity through Tfh cell 
regulation; moreover, these cells are resistant to classical 
anti-CD20 therapy [93]. Firmly understanding the ontogeny 
of these B cells and their relationship to other B-cell subsets, 
including other Breg phenotypes is of paramount importance 
if we hope to be able to refine therapeutic strategies so as to 
augment anti-tumour protective immunity and dampen down 
autoimmune and hence toxic responses.
Finally, large scale prospective and careful B-cell sub-
type specific and microenvironment segment specific 
analyses are required in lung cancer and in other cancers 
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to clarify the role of B cells in modulating the responsive-
ness to checkpoint blockade and in mediating the toxicity to 
these therapies. These studies will define the role of B-cell-
targeted strategies in augmenting the activity of, reducing 
resistance to and the ameliorating toxicity of this crucial 
class of anti-cancer agents.
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